Lumos Pharma(LUMO) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024 at 8:30AM ET AUSTIN, TX, May 14, 2024 (GLOBE NEWSWIRE) – Lumos P ...